Shanghai Yaoyuan Biotechnology

Shanghai Yaoyuan Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases and chronic conditions. The company specializes in developing multi-target agonists, particularly targeting the GLP-1, GIP, and glucagon receptors to treat obesity and type 2 diabetes. Their pipeline includes several next-generation candidates designed to improve metabolic health and weight management with enhanced efficacy and safety profiles. Based in Shanghai, the company leverages its internal R&D capabilities to advance programs from early discovery through clinical proof-of-concept.